Using a surgically induced endometriosis model [25], [42], we first showed that treatment with LXA4 reduced the volume of endometriotic lesions in part by attenuating pro-inflammatory (IL-1β and IL-6) and pro-angiogenic (VEGF) mediators in endometriotic lesions and PFCs. Here, IL1B is linked to endometriosis.